Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy. * ECOG PS 0-1 * 70 years of age or older * Must have measurable disease * ANC \> 1500, platelets \> 100,000 * Total bilirubin \</= 1.5, SGOT \* SGPT \< 5 x ULN * Able and willing to swallow and absorb oral medication * Able and willing to sign consent * Request archival diagnostic tissue for EGFR expression but not required Exclusion Criteria: * Proteinuria as demonstrated by UPC ratio \>/= 1.0 * Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide) * Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic) * History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation * Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment. * Current, ongoing treatment with full dose warfarin or equivalent * Current(within 10 days)use of aspirin (\> 325mg/day) or other NSAID with antiplatelet activity * History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD * Known CNS disease except for treated brain mets. * Squamous cell histology * Blood pressure \> 150/100 that cannot be ameliorated with standard anti-hypertensives * History of hypertensive crisis or hypertensive encephalopathy * NYHA grade II or \> CHF * History of MI within 6 months of enrollment * Major surgery, open biopsy, significant trauma within 28 days of enrollment * Pregnancy, lactation * Abdominal or other fistula, abcess, perforation